Moderna in Discussions to Supply Japan with Doses of its COVID-19 Vaccine Candidate

Article

The vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval.

Moderna announced on Aug. 28, 2020 that it is in discussions with the Ministry of Health, Labour and Welfare of Japan (MHLW) to purchase 40 million or more doses of mRNA-1273, Moderna’s COVID-19 vaccine candidate.

Through the agreement, the vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval, a Moderna press release said.

Source: Moderna

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
David Fairen-Jimenez
William K. Oh, MD
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.